Comparative Pharmacology
Head-to-head clinical analysis: DYAZIDE versus HYDROPANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYAZIDE versus HYDROPANE.
DYAZIDE vs HYDROPANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dyazide is a combination of hydrochlorothiazide, a thiazide diuretic that inhibits the Na+/Cl- cotransporter in the distal convoluted tubule, reducing sodium and water reabsorption; and triamterene, a potassium-sparing diuretic that blocks epithelial sodium channels in the collecting duct, reducing potassium excretion.
Thiazide diuretic; inhibits sodium chloride cotransporter in distal convoluted tubule, increasing excretion of sodium and water, and reducing plasma volume.
1-2 capsules orally once daily; each capsule contains hydrochlorothiazide 25 mg and triamterene 50 mg.
50–100 mg orally once daily, maximum 200 mg daily
None Documented
None Documented
Triamterene: 1.5–2.5 hours; hydrochlorothiazide: 6–15 hours. Clinical dosing typically once daily.
Terminal elimination half-life is approximately 8-15 hours in patients with normal renal function; may be prolonged in renal impairment.
Renal: triamterene ~80% (as metabolites and parent), hydrochlorothiazide >95% unchanged.
Renal (approximately 50% as unchanged drug) and hepatic metabolism to inactive metabolites; fecal elimination accounts for about 10%.
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic